Results Recap: RESCUE Shows Medtronic Valiant Captivia Stent Graft Treats Blunt Thoracic Injury
Executive Summary
This week's edition of Medtech Insight's Results Recap, the weekly roundup of major device trial results from MedDeviceTracker, includes medical device trial results announced from Jan. 25 through Jan. 31. After a flood of data last week from the Leipzig Interventional Course (LINC), this week’s list has just two entries: Medtronic announced new results supporting the long-term durability, safety, and efficacy of its Valiant Captivia thoracic stent graft system for the treatment of blunt thoracic aortic injury and Levita Magnetics announced the publication of a retrospective review of 73 bariatric procedures with its Levita magnetic surgical system.
You may also be interested in...
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.
Cardio Conversations: ‘Much More Than Just A Patch,’ iRhythm CEO Blackford Talks AI Arrhythmia Diagnostics
iRhythm CEO Quentin Blackford returned to Medtech Insight’s Cardio Conversations podcast to talk about the launch of his company’s new Zio monitor patch supported by a sophisticated neural network. He also addressed the company’s plans to improve its position in the mobile cardiac telemetry market, the impact of pulsed field ablation on the cardiac monitoring business, and more.